More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$64531437
EPS
-1.48
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
1.356252
Previous close
$1.14
Today's open
$1.16
Day's range
$1.16 - $1.26
52 week range
$0.96 - $1.88
show more
CEO
David H. Mack
Employees
47
Headquarters
Princeton, NJ
Exchange
Nasdaq Global Select
Shares outstanding
53331766
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • 3 hours ago

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Investment Research • Jun 10, 2026

PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair
GlobeNewsWire • Apr 22, 2026

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.
GlobeNewsWire • Mar 6, 2026

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated data from the Phase 2 pivotal portion of the ongoing PYNNACLE clinical trial. Results were presented today in an oral presentation by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts. The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.
GlobeNewsWire • Oct 24, 2025

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that two abstracts have been accepted for oral and poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 2025 in Boston, MA.
GlobeNewsWire • Oct 13, 2025

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
PMV Pharmaceuticals, Inc. PMVP on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Benzinga • Sep 10, 2025

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PRINCETON, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.
GlobeNewsWire • Sep 10, 2025

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps
PMV Pharmaceuticals (PMVP) Q2 Loss Jumps
The Motley Fool • Aug 7, 2025

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
GlobeNewsWire • Aug 7, 2025

¹ Disclosures

Open an M1 investment account to buy and sell PMV Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.